Li Ding, PhD

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine

Research Interest

Identifying and characterizing somatic/germline genetic changes relevant to cancer initiation and progression as well as drug response by integrating various data types, including DNA, RNA and proteomics data. Developing algorithms to facilitate the translation of genomic findings to clinical practice.

Education

1998: PhD, biochemistry, University of Utah, Salt Lake City

Training

1998 - 2999: Postdoctoral fellow, biochemistry, Stanford University, Palo Alto, Calif.

Selected Research Publications

Epigenetic regulation during cancer transitions across 11 tumour types.

Terekhanova NV, Karpova A, Liang WW, [...] Ding L
Nature 2023

High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.

Storrs EP, Chati P, Usmani A, [...] Ding L, [...] Chaudhuri AA
NPJ Precis Oncol 2023

Deep learning integrates histopathology and proteogenomics at a pan-cancer level.

Wang JM, Hong R, Demicco EG, [...] Ding L, [...] Fenyö D
Cell Rep Med 2023

Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.

Liang WW, Lu RJ, Jayasinghe RG, [...] Ding L
Cancer Cell 2023

Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC.

Baer JM, Zuo C, Kang LI, [...] Ding L, [...] DeNardo DG
Nat Immunol 2023

Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.

Wu Y, Terekhanova NV, Caravan W, [...] Ding L, Chen F
Nat Commun 2023

Clonal Hematopoiesis and Risk of Incident Lung Cancer.

Tian R, Wiley B, Liu J, [...] Ding L, [...] Cao Y
J Clin Oncol 2023

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.

Yao L, Jayasinghe RG, Lee BH, [...] Ding L
Cancer Res Commun 2022

Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer.

Cui Zhou D, Jayasinghe RG, Chen S, [...] Ding L
Nat Genet 2022

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.

O'Neal J, Ritchey JK, Cooper ML, [...] Ding L, [...] DiPersio JF
Leukemia 2022

Cancer proteogenomics: current impact and future prospects.

Mani DR, Krug K, Zhang B, [...] Ding L, [...] Carr SA
Nat Rev Cancer 2022

LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint.

McKerrow W, Wang X, Mendez-Dorantes C, [...] Ding L, [...] Fenyö D
Proc Natl Acad Sci USA 2022

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.

Dong L, Lu D, Chen R, [...] Ding L, [...] Fan J
Cancer Cell 2022

Pollock: fishing for cell states.

Storrs EP, Zhou DC, Wendl MC, [...] Ding L
Bioinform Adv 2022

Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.

Devarakonda S, Li Y, Martins Rodrigues F, [...] Ding L, Govindan R
J Clin Oncol 2021

View All Publications